Does Biosilicon deliver? Uni of Pittsburgh to investigate
Friday, 21 May, 2004
Nanotechnology company pSivida's (ASX: PSD) UK subsidiary pSiMedica has signed a collaborative agreement with the University of Pittsburgh to evaluate the use of BioSilicon as a delivery platform for the university's proprietary DNA vaccine technology.
The company will work with the laboratory of Prof Ted Ross, which has experience in developing DNA vaccines for viral diseases to build on prior work performed by pSiMedica on the loading into and release of DNA from BioSilicon matrices to effectively produce the immunogen carried by the DNA sequence.
pSivida managing director Gavin Rezos said the agreement demonstrated the increasing profile of pSivida and pSiMedica in the US.
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
